|
|
|
AUTHOR(S): Hardisman Dasman, Wirsma Arif Harahap, Daan Khambri
|
|
TITLE |
 PDF |
|
ABSTRACT Background: Breast cancer is the most prevalent cancer in women and one of Indonesia's leading causes of death. Cancer has various clinical courses, molecular variations, and outcomes, which are not well understood and presented in the Indonesian context. This study aimed to determine breast cancer clinicopathology and the association to the treatment outcome or event of recurrence in Indonesia. Methods: In this cohort study, we followed up 418 breast cancer patients from three major hospitals in West Sumatra Province of Indonesia with stage I-IV who had definitive treatment in 2017-2018. Demographic data, cancer stage, and different histopathology examination results were collected from the medical records. We followed up with the patients for two years in 2019-2020 to assess the cancer survival outcome. Bivariate analysis was conducted to determine the association between the histopathology profiles and cancer survival outcomes. Multivariate analysis with logistic regression was also performed to see the dominant factor. Results: The cases were mostly age >50 years (54.1%), cancer stage IIIB (34.0%), lymphovascular invasion (LVI) negative (77.8%), estrogen receptor (ER) positive (56.9%), progesterone receptor (PR) positive (57.9%), HER2 negative (55.5%), and molecular subtype Luminal B (49.5%). Two years survival was 85.2% or with a recurrent rate of 14.8%. There was no association between age, LVI, PR, and HER2+ and cancer survival. By contrast, there was a significant statistical association to ER (p=0.002), cancer stage (p=0.040), molecular subtype (0.001), in which the survival was higher in luminal A subtype (93.8%), cancer stage-I (100.0%), and ER Positive (89.9%). Multivariate analysis also showed the cancer stage was the dominant factor for survival. Conclusion: The study revealed that the association of clinicopathology and molecular markers to cancer survival varied, in which the lower cancer stage, luminal A subtype, and ER-positive are most likely to have a better outcome. A further multi-center study is necessary to evaluate in Indonesian nationwide outcomes. |
|
KEYWORDS Breast cancer; histopathology; outcome; recurrence |
|
|
|
Cite this paper Hardisman Dasman, Wirsma Arif Harahap, Daan Khambri. (2021) Clinicopathology Profiles and Outcome of Breast Cancer in Indonesian National Health Insurance Patients. International Journal of Oncology and Cancer Therapy, 5, 1-8 |
|
|
